



6. Brief CV for each group leader (max. 1 page per partner): *Brief CV for each group leader including a description of the main domain of research and a list of the 5 most relevant publications.*

Biographical Sketch Prof. Dr. Julia Stingl (formerly Kirchheiner)

Date of Birth: July 28, 1971
Place of Birth: Nürnberg, Germany
Citizenship: German

University Education:
1990-1991 University Erlangen-Nürnberg school of Chemistry
1991-1997 University of Frankfurt/Main Medical school

Degrees:
1997 *Doctor of Medicine*, University of Frankfurt/Main Medical School, Frankfurt, Germany
2004 *Private Dozent (Habilitation)*, Charité University medicine, Berlin, Germany
2006 *Professor of Clinical Pharmacology*, University of Ulm
2013 *Professor of Translational Pharmacology*, Medical Faculty University Bonn

Board Certification:
2003 Clinical Pharmacology

Professional Experience:
1997-1999 Residency in Psychiatry, Psychiatric university hospital, Freie Universität Berlin, Berlin, Germany (Prof. H. Helmchen)
1999-2003 Training in Clinical Pharmacology, Charité University Medicine, Berlin, Germany (Prof. I. Roots)
2004-2006 Scientific postdoctoral fellow, Department of Pharmacology, University of Cologne, Köln, Germany (Prof. E. Schömig)
2006-2013 Professor of Clinical Pharmacology, Department of Natural Medicine and Clinical Pharmacology, University of Ulm, Germany
March - April 2009 Research sabbatical at the Office of Clinical Pharmacology, Centre for Drug Evaluation and Research, Food and Drug Administration, Washington, US
Since 2013 Professor and director of the division of research, Federal Institute for Drugs and Medical devices, Bonn, Germany

Major scientific interests:
Pharmacogenetics of drug metabolizing enzymes, pharmacogenetic mechanisms involved in psychotropic drug response and the translation of pharmacogenetic diagnostics into clinical guidelines. In particular, drug metabolism in the brain and pharmacological neuroimaging for the study of variation in central nervous drug effects and for individualized treatment of mental disorder.

5 Publications

- 1: Stingl JC, Brockmöller J, Viviani R. Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function. *Mol Psychiatry*. 2013 Mar;18(3):273-87.
- 2: Viviani R, Abler B, Seeringer A, Stingl JC. Effect of paroxetine and bupropion on human resting brain perfusion: an arterial spin labeling study. *Neuroimage*. 2012 Jul 16;61(4):773-9.

3: Stingl JC, Esslinger C, Tost H, Bilek E, Kirsch P, Ohmle B, Viviani R, Walter H, Rietschel M, Meyer-Lindenberg A. Genetic variation in CYP2D6 impacts neural activation during cognitive tasks in humans. *Neuroimage*. 2012 Feb 1;59(3):2818-23.

4: Stingl JC, Viviani R. CYP2D6 in the brain: impact on suicidality. *Clin Pharmacol Ther*. 2011 Mar;89(3):352-3.

5: Abler B, Seeringer A, Hartmann A, Grön G, Metzger C, Walter M, Stingl J. Neural correlates of antidepressant-related sexual dysfunction: a placebo-controlled fMRI study on healthy males under subchronic paroxetine and bupropion. *Neuropsychopharmacology*. 2011 Aug;36(9):1837-47.